Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 3
1999 2
2000 3
2003 1
2006 1
2007 4
2008 1
2010 1
2011 2
2012 2
2015 3
2016 1
2017 3
2018 1
2020 3
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Urm1, not quite a ubiquitin-like modifier?
Kaduhr L, Brachmann C, Ravichandran KE, West JD, Glatt S, Schaffrath R. Kaduhr L, et al. Among authors: brachmann c. Microb Cell. 2021 Sep 21;8(11):256-261. doi: 10.15698/mic2021.11.763. eCollection 2021 Nov 1. Microb Cell. 2021. PMID: 34782858 Free PMC article.
Patterning the fly eye: the role of apoptosis.
Brachmann CB, Cagan RL. Brachmann CB, et al. Trends Genet. 2003 Feb;19(2):91-6. doi: 10.1016/S0168-9525(02)00041-0. Trends Genet. 2003. PMID: 12547518 Review.
E2/E3-independent ubiquitin-like protein conjugation by Urm1 is directly coupled to cysteine persulfidation.
Ravichandran KE, Kaduhr L, Skupien-Rabian B, Shvetsova E, Sokołowski M, Krutyhołowa R, Kwasna D, Brachmann C, Lin S, Guzman Perez S, Wilk P, Kösters M, Grudnik P, Jankowska U, Leidel SA, Schaffrath R, Glatt S. Ravichandran KE, et al. Among authors: brachmann c. EMBO J. 2022 Oct 17;41(20):e111318. doi: 10.15252/embj.2022111318. Epub 2022 Sep 14. EMBO J. 2022. PMID: 36102610 Free PMC article.
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, Miller CB, Rivera CE, Fleischman AG, Goel S, Heaney ML, O'Connell C, Arcasoy MO, Zhang Y, Kawashima J, Ganz T, Kowalski M, Brachmann CB. Oh ST, et al. Among authors: brachmann cb. Blood Adv. 2020 Sep 22;4(18):4282-4291. doi: 10.1182/bloodadvances.2020002662. Blood Adv. 2020. PMID: 32915978 Free PMC article. Clinical Trial.
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.
Shah MA, Cunningham D, Metges JP, Van Cutsem E, Wainberg Z, Elboudwarej E, Lin KW, Turner S, Zavodovskaya M, Inzunza D, Liu J, Patterson SD, Zhou J, He J, Thai D, Bhargava P, Brachmann CB, Cantenacci DVT. Shah MA, et al. Among authors: brachmann cb. J Immunother Cancer. 2021 Dec;9(12):e003580. doi: 10.1136/jitc-2021-003580. J Immunother Cancer. 2021. PMID: 34893523 Free PMC article. Clinical Trial.
36 results